1. Search Result
Search Result
Results for "

diagnosis

" in MedChemExpress (MCE) Product Catalog:

126

Inhibitors & Agonists

6

Screening Libraries

13

Fluorescent Dyes

4

Biochemical Assay Reagents

21

Peptides

1

Inhibitory Antibodies

23

Natural
Products

4

Isotope-Labeled Compounds

9

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P11024

    Folate Receptor (FR) Cancer
    NVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research .
  • HY-P3441A

    FAP Cancer
    3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .
  • HY-P10734

    Peptides
    NODAGA-RGD is a peptide that can be radiolabeled and used as a radiotracer for positron emission tomography (PET) diagnosis .
  • HY-B1493

    Peptides Endocrinology
    Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. The bentiromide test is an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency by outpatient test of chymotrypsin function .
  • HY-P4091
    LSD

    Biochemical Assay Reagents Cancer
    LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
  • HY-P10501A

    Antifolate Cancer
    FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
  • HY-P10369

    Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cardiovascular Disease Inflammation/Immunology
    Betiatide, as a chelating agent for Technetium-99m ( 99mTc), is used to prepare 99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P3441

    FAP Cancer
    3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .
  • HY-P11277

    Peptides Cancer
    Pocuvotide satetraxetan is an anticancer agent. Pocuvotide satetraxetan labeled with 177Lu can be used for imaging diagnosis .
  • HY-114133

    Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( 99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
  • HY-P10501

    Antifolate Cancer
    FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
  • HY-P10220

    Radionuclide-Drug Conjugates (RDCs) TREM receptor Cancer
    NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium ( 68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
  • HY-B1493R

    Biochemical Assay Reagents Reference Standards Endocrinology
    Bentiromide (Standard) is the analytical standard of Bentiromide. This product is intended for research and analytical applications. Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. The bentiromide test is an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency by outpatient test of chymotrypsin function .
  • HY-P10561

    Peptides Cancer
    CPK peptide is a tumor-localizing peptide. CPK peptide specifically binds to the monocarboxylate transporter 1 (MCT1) receptor, which is overexpressed in many human colon cancer cell lines but not in normal cells. CPK peptide can be used in tumor diagnosis research .
  • HY-P4091A

    Biochemical Assay Reagents Cancer
    LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
  • HY-W665456

    Drug Intermediate Others
    Fmoc‑PNA‑U‑OH is a peptide nucleic acid monomer that can be used for the synthesis of peptide nucleic acids (PNAs). Fmoc‑PNA‑U‑OH exhibits specific binding to adenine, resistance to enzymatic degradation, and strong hybridization properties. Fmoc‑PNA‑U‑OH can be applied in research fields such as gene diagnosis, molecular biology, and antisense therapy.
  • HY-P11577

    MMP Biochemical Assay Reagents Cancer
    TGGGPLGVARGKGGC is a polypeptide that can be specifically cleaved by MMP-9. TGGGPLGVARGKGGC modifies manganese dioxide supraparticles. TGGGPLGVARGKGGC can be used in the research of early cancer diagnosis .
  • HY-P11680

    DNA/RNA Synthesis Others
    BOC-PNA-thioU(PMB)-OH is a peptide nucleic acid (PNA) monomer characterized by a PMB protecting group on its thiouracil, which enhances its binding affinity to adenine. BOC-PNA-thioU(PMB)-OH exhibits excellent resistance to enzymatic degradation and strong hybridization properties, making it valuable for applications in gene diagnosis, antisense therapy, and other molecular biology fields requiring higher binding strength and greater functionalization.
  • HY-W540123

    Biochemical Assay Reagents Cancer
    Fmoc-PNA-A(Bhoc)-OH is a protected peptide nucleic acid (PNA) monomer carrying an adenine base. Fmoc-PNA-A(Bhoc)-OH contains Fmoc and benzhydryloxycarbonyl (Bhoc) protecting groups, and serves as a standard building block designed specifically for solid-phase PNA synthesis. Fmoc-PNA-A(Bhoc)-OH can be efficiently used to synthesize PNA-based sequence-specific hybridization probes. These probes have broad applications in molecular biology research; for example, they can be used in HER2-expressing tumor-related studies, providing tools for disease diagnosis and mechanism exploration .
  • HY-P10989

    Peptides Cancer
    NG2 binding peptide is a short peptide that specifically recognizes NG2 proteoglycan and can be obtained by phage screening technology. NG2 binding peptide interacts with NG2 binding sites to achieve precise targeting of tumor angiogenesis in vitro and in vivo. NG2 binding peptide exhibits significant homing ability in wild-type tumor-bearing mice, but has no localization effect in NG2 knockout mice. Due to the tissue specificity of NG2 expression, NG2 binding peptide can be used in scenarios such as tumor targeted therapy, drug delivery, and molecular imaging diagnosis .
  • HY-P11590

    EGFR Cancer
    WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: